TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of renal cell carcinoma and urothelial bladder cancer.

LEARNING OBJECTIVES

• Evaluate recently presented data with adjuvant anti-PD-1 antibody-based therapies for patients with renal cell carcinoma (RCC) at high risk for recurrence after nephrectomy, and consider the current role of this strategy.
• Appraise available clinical trial data evaluating anti-PD-1/PD-L1 antibody/multikinase inhibitor combinations for previously untreated metastatic RCC, and counsel patients regarding the risks and benefits of these novel regimens.
• Review the biologic rationale underlying the investigation of anti-PD-1/anti-CTLA-4/multikinase inhibitor combination therapy as first-line treatment for patients with metastatic RCC, and appreciate emerging research documenting the effectiveness of this approach. 
• Develop a rational approach to the sequencing of systemic therapies for patients with advanced RCC who experience disease progression on first-line treatment, incorporating multikinase inhibitors, mTOR inhibitors, immunotherapeutic agents and other therapies. 
• Consider available data supporting the use of anti-PD-1 antibody therapy for high-risk non-muscle-invasive bladder cancer that is unresponsive to BCG, and determine how this strategy can be appropriately integrated into patient care.
• Assess available clinical research findings with and the current clinical role of adjuvant anti-PD-1 antibody therapy for high-risk muscle-invasive bladder cancer.
• Review clinical trial evidence with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy in the treatment of newly diagnosed metastatic urothelial bladder cancer (UBC), and determine the current utility of these agents in clinical practice. 
• Recall pivotal clinical trial findings leading to the FDA approval of novel compounds with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and identify patients for whom these approaches would be appropriate. 
• Appreciate the biologic rationale for combining anti-PD-1/PD-L1 antibodies with other systemic agents with established efficacy for UBC, and assess the current and potential roles of these regimens in patient care. 
• Reflect on available and emerging data with investigational agents and strategies currently in testing for RCC and UBC, and refer eligible patients for clinical trial participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Presentations Program: This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty and moderator reported relevant financial relationships with ineligible entities:

Matthew Milowsky, MD
George Gabriel and Frances Gable Villere Distinguished Professor
Vice Chief for Research and Education
Section Chief, Genitourinary Oncology
UNC Division of Oncology
Co-Lead, Clinical and Translational Research
Co-Director, Urologic Oncology Program
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Advisory Committee and Consulting Agreement: Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Contracted Research: ALX Oncology, Arvinas, Bristol-Myers Squibb Company, Clovis Oncology, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mirati Therapeutics Inc, Seagen Inc; Stock Options/Ownership — Public Company: Gilead Sciences Inc, Merck, Pfizer Inc; Nonrelevant Financial Relationship: Alliance for Clinical Trials in Oncology, Alliance Foundation Trials LLC, Elsevier (Co-Editor-in-Chief, Clinical Genitourinary Cancer), Hoosier Cancer Research Network Inc, Medscape (educational videos).

Thomas Powles, MBBS, MRCP, MD
Director of Barts Cancer Institute
Queen Mary University of London
London, United Kingdom

Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Travel/Accommodation/Expenses: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme LLC, Pfizer Inc, Roche Laboratories Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Exelixis Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Release date: April 2023
Expiration date: April 2024